3.1. Synergistic Effects on Cell Viability in AML Cell Lines Treated with the MCL1 Inhibitor S63845 and the MEK Inhibitor Trametinib or the MDM2 Inhibitor HDM201. This evidence concerns the gene MCL1 and acute myeloid leukemia.